Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

(2016) Brenda J. Weigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Frontline therapy of multiple myeloma

(2015) P. Moreau et al.   BLOOD

A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study

(2015) Terzah M. Horton et al.   BRITISH JOURNAL OF HAEMATOLOGY

WEE1 Kinase As a Target for Cancer Therapy

(2015) Sabine Mueller et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression

(2015) Klaudia Skrzypek et al.   Oncotarget

Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma

(2015) Diana Yu et al.   Scientific Reports

Advances in Therapy for Pediatric Sarcomas

(2014) Aaron Weiss et al.   Current Oncology Reports

Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death

(2013) Christopher J Del Nagro et al.   CELL CYCLE

Wee1 kinase as a target for cancer therapy

(2013) Khanh Do et al.   CELL CYCLE

A Proposal Regarding Reporting of In Vitro Testing Results

(2013) M. A. Smith et al.   CLINICAL CANCER RESEARCH

Expression and clinical relevance of MET and ALK in Ewing sarcomas

(2013) Emmy D.G. Fleuren et al.   INTERNATIONAL JOURNAL OF CANCER

Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas

(2013) Jenny M. Kreahling et al.   PLoS One

The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation

(2013) K Miekus et al.   Cell Death & Disease

Epidemiology and therapies for metastatic sarcoma

(2013) Damon Reed et al.   Clinical Epidemiology

Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls

(2013) Ashley R. P. Hinson et al.   Frontiers in Oncology

Effect of inhibition of the Ubiquitin-Proteasome System and Hsp90 on growth and survival of Rhabdomyosarcoma cells in vitro

(2012) Marica Peron et al.   BMC CANCER

Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

(2012) Douglas S. Hawkins et al.   PEDIATRIC BLOOD & CANCER

WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

(2011) P. C. De Witt Hamer et al.   CLINICAL CANCER RESEARCH

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

(2011) R. Beverly Raney et al.   JOURNAL OF CLINICAL ONCOLOGY

MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells

(2011) J. M. Kreahling et al.   MOLECULAR CANCER THERAPEUTICS

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

(2009) Carola A.S. Arndt et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma

(2008) Francesca Bersani et al.   EUROPEAN JOURNAL OF CANCER

Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups

(2008) Odile Oberlin et al.   JOURNAL OF CLINICAL ONCOLOGY